The earnings call highlighted strong revenue growth, successful regulatory approvals, and promising advancements in the clinical and preclinical pipeline, supported by robust partnerships. However, there were concerns about reduced revenue in specific areas and ongoing cash burn. Additionally, questions about potential delays in the HERIZON-GEA-01 study results were raised.

Company Guidance -

Q3 2025

During the Zymeworks Second Quarter 2025 Results Conference Call, several key metrics and updates were provided. The company reported a significant increase in total revenue, reaching $48.7 million, compared to $19.2 million in the same period of 2024. This increase was largely attributed to a $20 million milestone payment from BeOne and the recognition of $18.3 million in deferred revenue. Operating expenses decreased by 20% to $49.4 million, with net income reaching $2.3 million, a substantial improvement from a net loss of $37.7 million the previous year. As of June 30, 2025, Zymeworks' cash resources stood at $333.4 million, up from $324.2 million at the end of 2024. The company anticipates that its cash resources will fund operations into the second half of 2027. Key developments included IND clearance for ZW251, progress in the Phase I trials of ZW171 and ZW191, and conditional approvals for zanidatamab in China and Europe, which are expected to increase royalty revenues in the coming years.

Strong Financial Performance

Total revenue was $48.7 million in Q2 2025 compared to $19.2 million in Q2 2024, primarily due to milestone payments and increased royalty revenues.

Zanidatamab Progress

Zanidatamab received conditional regulatory approvals in China and Europe for second-line HER2-positive biliary tract cancer, expanding international patient access and potential future royalties.

Expansion in Clinical Programs

IND clearance of ZW251, the second TOPO1 ADC candidate, was announced for the treatment of HCC, marking it as the third active Phase I trial in 2025.

Clinical and Preclinical Pipeline Developments

ZW171 and ZW191 are progressing in Phase I studies, and ZW1528 is being developed for COPD with promising preclinical data.

Partnership Success

Partnerships with companies like Jazz and J&J are generating milestones and royalties, contributing significantly to revenue.

Financial Health

Cash resources increased to $333.4 million as of June 30, 2025, ensuring funding for planned operations into the second half of 2027.

R&D Pipeline Momentum

Strong momentum observed in R&D pipeline, particularly with IND clearance of ZW251 and promising preclinical data for ZW1528.

Zymeworks (ZYME) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ZYME Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.29 / -	-0.39	―	―	―
Aug 07, 2025	2025 (Q2)	-0.48 / 0.03	-0.49	106.12% (+0.52)
May 08, 2025	2025 (Q1)	-0.68 / -0.30	-0.42	28.57% (+0.12)
Mar 05, 2025	2024 (Q4)	-0.10 / -0.31	-0.2	-55.00% (-0.11)
Oct 31, 2024	2024 (Q3)	-0.40 / -0.39	-0.41	4.88% (+0.02)
Aug 01, 2024	2024 (Q2)	-0.42 / -0.49	-0.76	35.53% (+0.27)
May 02, 2024	2024 (Q1)	-0.32 / -0.42	-0.37	-13.51% (-0.05)
Mar 06, 2024	2023 (Q4)	-0.41 / -0.20	4.65	-104.30% (-4.85)
Nov 07, 2023	2023 (Q3)	-0.47 / -0.41	-0.72	43.06% (+0.31)
Aug 10, 2023	2023 (Q2)	-0.47 / -0.76	-0.97	21.65% (+0.21)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ZYME Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$12.16	$12.02	-1.15%
May 08, 2025	$11.32	$11.30	-0.18%
Mar 05, 2025	$13.18	$12.13	-7.97%
Oct 31, 2024	$13.70	$13.28	-3.07%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Zymeworks Inc (ZYME) report earnings?

Zymeworks Inc (ZYME) is schdueled to report earning on Nov 11, 2025, Before Open (Confirmed).

What is Zymeworks Inc (ZYME) earnings time?

Zymeworks Inc (ZYME) earnings time is at Nov 11, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ZYME EPS forecast?

ZYME EPS forecast for the fiscal quarter 2025 (Q3) is -0.29.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing